Education
About Us
Working with TipRanks
Follow Us
Soligenix Inc (SNGX)
NASDAQ:SNGX
SNGX Stock Chart & Stats
$1.44
-$0.10(-2.65%)
At close: 4:00 PM EST
$1.44
-$0.10(-2.65%)
Day’s Range― - ―
52-Week Range$1.02 - $6.23
Previous CloseN/A
Volume55.16K
Average Volume (3M)176.54K
Market Cap
$10.99M
Enterprise Value$853.60K
Total Cash (Recent Filing)$5.10M
Total Debt (Recent Filing)$411.40K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Mar 31, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding10,086,130
10 Day Avg. Volume167,762
30 Day Avg. Volume176,538
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.53
Enterprise Value/Market Cap0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.21K
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ThermoVax Vaccine Stability PlatformThermoVax reduces cold-chain dependency, a structural advantage for vaccine distribution and biodefense programs. Heat-stable formulations can attract government funding and strategic partners, creating durable licensing and collaboration opportunities that persist beyond any single clinical readout.
Confirmatory Phase 3 Progress On HyBryteCompleting planned enrollment for the FLASH2 confirmatory Phase 3, which mirrors a prior statistically significant study, materially de-risks the regulatory pathway. A positive confirmatory result would enable commercialization, licensing, or government uptake, fundamentally changing the company's long-term cash generation prospects.
Improving Leverage And Exchange ComplianceMarked debt reduction and positive equity lower insolvency and refinancing risk, improving strategic flexibility. Regaining Nasdaq compliance further reduces listing risk and preserves access to public capital markets and partner credibility, supporting longer-term financing and partnership options.
Bears Say
No Revenue And Persistent Cash BurnZero revenue and roughly −$8.4M operating free cash flow in 2024 show structural negative cash generation. Persistent operating losses force continual external financing, limit investment in commercialization, and make sustainability highly contingent on positive trial outcomes or milestone payments.
Reliance On External Equity Financing (ATM Program)An active ATM program signals ongoing dependence on equity markets to fund operations. While flexible, repeated use is dilutive and indicates limited internal cash generation; long-term shareholder value is vulnerable if clinical progress does not convert into revenue or non-dilutive government contracts.
Binary, Small-scale Clinical-stage Business ModelAs a development-stage biotech with no approved products and a small team, the company faces a binary outcome set: success in trials or dependence on partners/financing. Limited commercial infrastructure and scale increase execution risk and lengthen time to self-sustaining revenues even if clinical results are favorable.
Soligenix News
SNGX FAQ
What was Soligenix Inc’s price range in the past 12 months?
Soligenix Inc lowest stock price was $1.02 and its highest was $6.23 in the past 12 months.
What is Soligenix Inc’s market cap?
Soligenix Inc’s market cap is $10.99M.
When is Soligenix Inc’s upcoming earnings report date?
Soligenix Inc’s upcoming earnings report date is Mar 31, 2026 which is in 42 days.
How were Soligenix Inc’s earnings last quarter?
Soligenix Inc released its earnings results on Nov 07, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.555 by -$0.025.
Is Soligenix Inc overvalued?
According to Wall Street analysts Soligenix Inc’s price is currently Undervalued.
Does Soligenix Inc pay dividends?
Soligenix Inc does not currently pay dividends.
What is Soligenix Inc’s EPS estimate?
Soligenix Inc’s EPS estimate is -0.56.
How many shares outstanding does Soligenix Inc have?
Soligenix Inc has 10,086,130 shares outstanding.
What happened to Soligenix Inc’s price movement after its last earnings report?
Soligenix Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.555. Following the earnings report the stock price went up 7.031%.
Which hedge fund is a major shareholder of Soligenix Inc?
Currently, no hedge funds are holding shares in SNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Soligenix Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
SNGX Stock 12 Month Forecast
Average Price Target
$10.00
▲(594.44% Upside)
Technical Analysis
Ownership Overview
3.86% Insiders
0.57% Mutual Funds
10.49% Other Institutional Investors
84.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---